Showing results (101-110 of 111) with videos related to
Sort By:
Pageof 12
Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.Nature Medicine|February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trialBenjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.Pageof 12